| Evaluation of human immunodeficiency virus biomarkers: inferences from interval and clinical cohort studies. | |
| | |
MedLine Citation:
|
PMID: 19478669 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Among individuals infected with the human immunodeficiency virus (HIV), biomarkers that predict mortality are also used to determine the time when antiretroviral therapy is initiated. No studies have evaluated the impact of the frequency of marker measurements for either their predictive value of mortality or how they may influence inference of the effect of therapy initiation in analyses from observational data. METHODS: We identified 244 persons who were contemporaneously enrolled in both the AIDS Link to the IntraVenous Experience (an interval cohort) and the Johns Hopkins HIV Clinical Cohort between 1995 and 2004. Data from each study were used separately in 2 ways. We applied time-dependent proportional hazards models to examine the predictive associations between markers and mortality, and marginal structural models to examine the causal inference of therapy on mortality. Biomarkers were used to derive the inverse probability weights. RESULTS: The timing frequencies of marker measurements in the interval cohort (CD4 interquartile range = 175-194 days) were less heterogeneous than in the clinical cohort (interquartile range = 38-121 days). Despite this, the results were concordant for CD4 (R = 0.537 [95% confidence interval = 0.345-0.707] and (R = 0.488 [0.297-0.666], respectively). Similar concordance was found for the HIV-1 RNA and hemoglobin analyses. When evaluating the causal effect of highly active antiretroviral therapy (HAART), the relative hazards were 0.34 for the interval cohort study (95% CI = 0.15-0.77) and 0.27 for the clinical cohort study (0.11-0.66). CONCLUSION: Utilizing a unique co-enrollment of patients in 2 different types of cohort studies, we find empirical evidence that inferences drawn from these different structures are similar. |
| | |
Authors:
|
Bryan Lau; Stephen J Gange; Gregory D Kirk; Richard D Moore |
Related Documents
:
|
10426909 - Sarcoidosis in a patient with aids: a manifestation of immune restoration syndrome. 14731169 - Determinants of long-term highly active antiretroviral treatment efficacy. 15853719 - Inpatient care of the hiv infected patient in the highly active antiretroviral therapy ... 17538879 - Virologic response to potent antiretroviral therapy and modeling of hiv dynamics in ear... 18240059 - The neuropathology of hiv/aids. 20005489 - Diagnosis and natural history of hiv-associated nephropathy. 23414499 - Racial/ethnic differences in the rates and correlates of hiv risk behaviors among drug ... 11516379 - Reconstructing the origins of human hepatitis viruses. 3163229 - Human immunodeficiency virus infection in hemophiliac patients. a three-year prospectiv... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Epidemiology (Cambridge, Mass.) Volume: 20 ISSN: 1531-5487 ISO Abbreviation: Epidemiology Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-08-14 Completed Date: 2009-12-22 Revised Date: 2012-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9009644 Medline TA: Epidemiology Country: United States |
Other Details:
|
Languages: eng Pagination: 664-72 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. blau1@jhmi.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
AIDS Serodiagnosis
/
methods Adult Biological Markers / blood CD4 Lymphocyte Count Cohort Studies Female HIV-1 / genetics, isolation & purification* Hemoglobins / analysis Humans Male Middle Aged Proportional Hazards Models Prospective Studies Questionnaires RNA, Viral / blood |
| Grant Support | |
ID/Acronym/Agency:
|
K01-AI071754/AI/NIAID NIH HHS; R01 DA004334/DA/NIDA NIH HHS; R01-DA04334/DA/NIDA NIH HHS; R01-DA11602/DA/NIDA NIH HHS; R01-DA12546/DA/NIDA NIH HHS; R56 DA004334/DA/NIDA NIH HHS; U01 AI042590-12/AI/NIAID NIH HHS; U01-AI069918/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Hemoglobins; 0/RNA, Viral |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intermittent pneumatic compression and pharmacologic thrombosis prophylaxis.
Next Document: Ambient air pollution and preterm birth: a time-series analysis.